These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38852673)

  • 41. Particulate-matter content of 11 cephalosporin injections: conformance with USP limits.
    Parkins DA; Taylor AJ
    Am J Hosp Pharm; 1987 May; 44(5):1111-8. PubMed ID: 3605122
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The incidence of coring with blunt versus sharp needles.
    Wani T; Wadhwa A; Tobias JD
    J Clin Anesth; 2014 Mar; 26(2):152-4. PubMed ID: 24582180
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of the in-line filters for the intravenous infusion of amphotericin B fluid.
    Hirakawa M; Makino K; Nakashima K; Kataoka Y; Oishi R
    J Clin Pharm Ther; 1999 Oct; 24(5):387-92. PubMed ID: 10583703
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparing visual inspection methods for parenteral products in hospital pharmacy: between reliability, cost, and operator formation considerations.
    Jambon A; Forat M; Marchand C; Morel C; Merienne C; Filali S; Pirot F
    Eur J Hosp Pharm; 2024 Sep; ():. PubMed ID: 38789246
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Particulate contamination in parenterals: current issues.
    Groves MJ
    Boll Chim Farm; 1991 Oct; 130(9):347-54. PubMed ID: 1799429
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Points to Consider: Best Practices to Identify Particle Entry Routes along the Manufacturing Process for Parenteral Formulations.
    Anger S; Begat C; Crnko V; Fantozzi G; Farach W; Fitzpatrick S; Gallagher B; Huelsmann S; Kinsey P; Langlade V; Lefevre G; Legendre E; McLean K; Miller J; Patel R; Perry A; Soukiassian H; Stanton A; Streich D; Timmons C; Vaneylen D; van Hoose T; Wildling L; Windover M
    PDA J Pharm Sci Technol; 2019; 73(6):635-647. PubMed ID: 31420504
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of factors influencing ampoule secondary particulate contamination. A strategy for its reduction in small volume parenterals.
    Bernuzzi M; Raggi P; Montanari L
    Boll Chim Farm; 1991 Sep; 130(8):323-8. PubMed ID: 1801862
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Utilization of the tyndall effect for enhanced visual detection of particles in compatibility testing of intravenous fluids: validity and reliability.
    Staven V; Waaseth M; Wang S; Grønlie I; Tho I
    PDA J Pharm Sci Technol; 2015; 69(2):270-83. PubMed ID: 25868993
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analysis of Particulate Matter in Liquid-Finished Dosage Forms.
    Duchek J; Havasi B
    PDA J Pharm Sci Technol; 2018; 72(6):608-625. PubMed ID: 29853612
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Parenteral handling precaution: particulate introduction resulting from needle sheath contamination.
    Baumgartner TG; Schmidt GL; Sitren HS; Cerda JJ
    Hosp Pharm; 1986 Apr; 21(4):323-6. PubMed ID: 10276290
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Particulate evaluation of parenteral nutrition solutions by electronic particle counting and scanning electron microscopy.
    Akers MJ; Schrank GD; Russell S
    Am J Hosp Pharm; 1981 Sep; 38(9):1304-7. PubMed ID: 6792911
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Particulate matter in small volume parenterals: evaluation of some technological and analytical aspects.
    Cirannni Signoretti E; Montanari I; Neri G; De Sena C; Alimonti S
    Boll Chim Farm; 1989 Feb; 128(2):65-70. PubMed ID: 2775519
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Monitoring of Visible Particles in Parenteral Products by Manual Visual Inspection-Reassessing Size Threshold and Other Particle Characteristics that Define Particle Visibility.
    Mazaheri M; Saggu M; Wuchner K; Koulov AV; Nikels F; Chalus P; Das TK; Cash PW; Finkler C; Levitskaya-Seaman SV; Case J; Parsons J; Gonzalez K
    J Pharm Sci; 2024 Mar; 113(3):616-624. PubMed ID: 37802369
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Particulate matter assessment of a clinical investigation on filtration and infusion phlebitis.
    Schroeder HG; DeLuca PP
    Am J Hosp Pharm; 1976 Jun; 33(6):543-6. PubMed ID: 1274972
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Defining unnecessary disinfection procedures for single-dose and multiple-dose vials.
    Buckley T; Dudley SM; Donowitz LG
    Am J Crit Care; 1994 Nov; 3(6):448-51. PubMed ID: 7834004
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Considerations for design and use of container challenge sets for qualification and validation of visible particulate inspection.
    Melchore JA; Berdovich D
    PDA J Pharm Sci Technol; 2012; 66(3):273-84. PubMed ID: 22634593
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Particulate contamination in parenteral nutrition solutions: still a cause for concern?
    Ball PA; Bethune K; Fox J; Ledger R; Barnett M
    Nutrition; 2001; 17(11-12):926-9. PubMed ID: 11744342
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Origin, result and measurement of USP "essentially free" inspection for visible contaminating particles.
    Knapp JZ
    PDA J Pharm Sci Technol; 2000; 54(3):218-32. PubMed ID: 10927913
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Parameter for assessing parenteral cleanliness based on particle-size distributions.
    Blanchard J; Schwartz JA; Byrne DM
    J Pharm Sci; 1977 Aug; 66(8):1083-6. PubMed ID: 894493
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Particulate and microbial contamination in in-use admixed intravenous infusions.
    Yorioka K; Oie S; Oomaki M; Imamura A; Kamiya A
    Biol Pharm Bull; 2006 Nov; 29(11):2321-3. PubMed ID: 17077539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.